Close mobile menu×
Close mobile menu

Howard J. Worman, MD

Board Certifications: 
Internal Medicine
Not Accepting New Patients
Profile Hero

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Internal Medicine

Clinical Expertise

  • Liver Disease
  • Internal Medicine

Education & Training

  • Pritzker School of Medicine at the University of Chicago
  • Internship: New York Hospital - Cornell Medical Center
  • Residency: New York Hospital-Cornell Medical Center
  • Fellowship: New York Hospital-Cornell Medical Center
  • Fellowship: Rockefeller University

Honors & Awards

  • Phi Beta Kappa, Cornell University, 1980
  • Bachelor of Arts cum laude in biology, Cornell University, 1981
  • Calvin Fentress Research Fellowship Award, University of Chicago, 1984
  • First Prize Midwest Student Medical Research Forum, 1985
  • Franklin McLean Award for meritorious medical student research, University of Chicago, 1985
  • Richard W. Reilly Award for outstanding aptitude in gastroenterology, University of Chicago, 1985
  • Trainee Award in Clinical Research, American Federation for Clinical Research, 1989
  • Henry Christian Award, American Federation for Clinical Research, 1990 Charles E. Culpeper Scholar in Medical Science, 1994
  • SmithKline Beecham Clinical Research Award, American Gastroenterological Association, 1994
  • Travel Award 16th International Congress of Biochemistry & Molecular Biology New Delhi, American Society For Biochemistry and Molecular Biology, 1994
  • Silberberg Award, Columbia University College of Physicians and Surgeons, 1995
  • Irma T. Hirschl Scholar, Irma T. Hirschl Trust, 1997
  • American Society for Clinical Investigation, 1998
  • Association of American Physicians, 2010

About Howard Worman

Howard J. Worman, M.D. is Professor of Medicine and Pathology and Cell Biology at Columbia University’s College of Physicians and Surgeons. Dr. Worman received his BA from Cornell University and MD from the University of Chicago Pritzker School of Medicine. He did clinical training in internal medicine at New York Hospital-Cornell Medical Center and postdoctoral research training in cell biology at Rockefeller University. He then obtained clinical training in liver diseases at the Mount Sinai Medical Center.

Dr. Worman is internationally recognized for his research in cell biology and hepatology. His laboratory research is focused on primarily on the cell biology of rare genetic diseases. These include different types of muscular dystrophy, cardiomyopathy, lipodystrophy and premature aging syndromes (progeria) . He also does research on non-alcoholic fatty liver disease and on the characterization of antibodies in autoimmune liver diseases. His clinical practice is primarily devoted to consultation in liver diseases.

Dr. Worman is an author on over 200 scientific publications. In 1998, he was elected to membership in the American Society for Clinical Investigator and, in 2010, to the Association of American Physicians. He has served on the Editorial Boards of Hepatology, Gastroenterology, Molecular Biology of the Cell and Journal of Autoimmunity and as a Section Editor of BMC Cell Biology. Dr. Worman is also author of the popular Liver Disorders and Hepatitis Sourcebook (McGraw-Hill, 2006).

Academic Titles

  • Professor of Medicine
  • Professor of Pathology & Cell Biology

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Research

Mutations in genes encoding the intermediate filament nuclear lamins and associated proteins cause a wide spectrum of diseases sometimes called laminopathies. These include various types of muscular dystrophy, cardiomyopathy, lipodystrophy, bone disorders and accelerated aging synndromes (progeria). Data explaining pathogenic mechanisms of laminopathies are only emerging. Our laboratory is focused on deciphering how mutations in genes encoding nuclear lamins and other nuclear envelope proteins cause disease. In particular, we are discovering alterations in cell signal transduction pathways and gene expression that occur as a result of abnormalities in the nuclear envelope. For example, we have shown that A-type lamin alterations that cause cardiomyopathy lead to abnormally activated MAP kinase activities in heart and that blocking these enzymes can prevent disease in a mouse model. Our long-term goal is to use this information to discover treatments for this the fascinating group of diseases associated with the nuclear envelope. We have also be characterizing nuclear envelope autoantigens in autoimmune liver diseases such a primary biliary cirrhosis and autoimmune hepatitis. In another new research project, we are various strains of mice to attempt to identify susceptibility genes for non-alcoholic steatohepatitis, a liver disease that occurs in some people who are obese and that also mimics aspects of alcoholic liver disease.

Research Interests

  • Our laboratory is interested in determining how mutations in genes encoding proteins of the inner nuclear membrane cause a wide variety of inherited diseases, including muscular dystrophies, cardiomyopathy, lipodystophy and accelerated aging disorders.
  • We are also intrested in liver diseases, including fatty liver disease and autoimmune liver diseasess such as primary biliary cirrhosis.

Grants

2R01AR048997 Worman (PI) 07/01/2002 - 06/30/2020
NIH/NIAMS: Pathogenesis of Emery-Dreifuss Muscular Dystrophy
The goals of this project are to examine the interaction between A-type lamins, emerin and LAP1 using genetic approaches in mice and biochemical and biophysical approaches in cells, to examine the binding of A-type lamins to ERK1/2 and to test how DUSP4 links activation of ERK1/2 to pathology in Emery-Dreifuss muscular dystrophy.

1R01AR068636-01 Worman; Gundersen (MPI) 09/01/2015 - 06/30/2020
NIH/NIAMS: Nuclear Movement LINC Complex and Emery-Dreifuss Muscular Dystrophy
The goal of this project is to test the hypothesis that in Emery-Dreifuss muscular dystrophy there is a link between defective nuclear movement and ERK1/2 activity in myoblasts and muscle fibers and to examine the movement of nuclei and migration of myoblasts in cells with disease-causing mutations.

5R01HD070713-04 Gundersen; Worman (MPI) 03/15/2011 - 01/31/2016
NIH/NICHD: The Nucleocytoskeleton in Progeria and Aging
The goal of this project is to determine how abnormalities in the nuclear lamina in Hutchinson-Gilford progeria syndrome and cause abnormalities in nuclear migration and in the dynamics of nuclear envelope proteins that link the nucleus to the cytoskeleton and relate this to physiological aging.  Dr. Worman shares the direct costs on this MPI grant with the other PI, Dr. Gundersen.

MDA 294537 Worman (PI) 05/01/2014 - 04/30/2017
Muscular Dystrophy Association: Emerin-LAP1 Interaction and X-linked Emery-Dreifuss Muscular Dystrophy
The goals of this project are to determine the smallest interacting domains of LAP1 and emerin and examine their interaction in transfected cells using fluorescence photobleaching methods, examine the effects of emerin and LAP1 depletion on AKT and ERK1/2 signaling and determine if pharmacological inhibition of ERK1/2 signaling and mTOR activity improve muscle function in mice lacking emerin and LAP1 from muscle.

EDMD REGISTRY AND DATABASE (Private)

Jul 1 2016 - Jun 30 2021

PATHOGENIC ROLE OF SELECTED CARDIAC MYOCYTE- AND FIBROBLAST-SPECIFIC EPIGENETIC CHANGES IN LAMINOPATHIES (Federal Gov)

Mar 15 2016 - Feb 28 2020

EMERIN-LAP 1 INTERACTION AND X-LINKED EMERY DREIFUSS MUSCULAR DYSTROPHY (Private)

May 1 2014 - Apr 30 2017

NUCLEOYTOPLASMIC INTERACTIONS AND DYNAMICS IN EMERY-DREIFUSS MUSCULAR DYSTROPHY (Federal Gov)

Sep 1 2007 - Jun 30 2016

THE NUCLEOCYTOSKELETON IN PROGERIA AND AGING (Federal Gov)

Mar 15 2011 - Jan 31 2016

DUSP4 IN THE PATHOGENESIS OF LMNA CARDIOMYOPATHY (Federal Gov)

Aug 1 2013 - Oct 31 2015

USE OF SELUMETINIB TO TREAT LMNA CARDIOMYOPATH (Private)

Aug 1 2013 - Jul 31 2015

TREATMENT OF INHERITED AND GENETIC CARDIOMYOPATHIES BY ERK OR JNK INHIBITION (Private)

Jun 28 2013 - Dec 27 2014

PRECLINICAL DEVELOPMENT OF NOVEL MED1/2 INHIBITORS TO TREAT INHERITED CARDIOMYOPA (Federal Gov)

Sep 1 2013 - Aug 31 2014

TRAINING PROGRAM IN MOLECULAR BASIS OF HEALTH AND DISEASE (Private)

Apr 1 2010 - Mar 31 2014

THERAPIES FOR INTERMEDIATE FILAMENT DISEASES (Private)

Jan 1 2012 - Dec 31 2013

LAP1 INVOLVEMENT IN THE PATHOLOGY OF EMERGY-DREIFUSS MASCULA R DYSTROPHY (Private)

Jul 1 2010 - Jun 30 2013

TREATMENT OF CARDIOMYOPATHY IN (Private)

Jul 1 2010 - Jun 30 2013

AGREEMENT FOR COLLABORATION SERVICES (Private)

Jan 1 2010 - Jun 30 2013

MOLECULAR AND CELLULAR PATHOGENSIS OF EMERY-DREIFUSS MUSCULA (Federal Gov)

Feb 1 2010 - Jan 31 2013

MAP KINASE SIGNALING INHIBITORS TO TREAT CARDIOMYOPATHY (Private)

Apr 23 2010 - Apr 22 2012

Selected Publications

SELECTED REVIEWS AND BOOKS

Gundersen GG, Worman HJ. Nuclear positioning. Cell 2013;152:1376-1389

Worman HJ. Nuclear lamins and laminopathies. J Pathol 2012;226:316-325

Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol 2010;2:a000760.

Dauer WT, Worman HJ. The nuclear envelope as a signaling node in development and disease. Dev Cell 2009;17:626-638

Worman HJ. Nuclear envelope autoantigens in primary biliary cirrhosis. Hepatol Res 2007;37 Suppl 3:S406-S411

Worman HJ. The Liver Disroders Sourcebook McGraw-Hill (2006)